Sign in Subscribe
Business planning

Sterilox Technologies: A UK Start-Up Success Story Born from Innovation and Perseverance

Strategic Insights

— 2 min read

Stoke-on-Trent's Sterilox Technologies has emerged as a remarkable example of a UK start-up that has successfully commercialized a patented technology for producing a cheap, effective, and non-toxic disinfectant with multiple uses. Founded on a Russian scientific innovation, Sterilox has relied heavily on UK universities and companies, such as Huntingdon Life Sciences, to develop and prove its technology. The company's initial focus on the UK hospital market has paid off, with its product now used in 100 NHS hospitals, giving the group almost 25% of the market.

Key Takeaways:

  • Sterilox Technologies has developed a patented electrolysis cell technology that produces super-oxidized water, a non-toxic and non-hazardous disinfectant.
  • The company's initial market focus was on the UK hospital market, where it established its product's reputation and gained traction.
  • Sterilox has overcome concerns about product reliability by outsourcing manufacturing to the UK subsidiary of Germany's Bran and Luebbe.
  • The company installs its generators in hospitals free of charge and charges for the disinfectant used, contributing to its rapid market penetration in the UK.
  • Growing industry worries about the adverse side-effects of rival disinfectants have further boosted Sterilox's market share in the UK.
  • The company's strategic partnership with Air Products, a $12bn US company, has diluted the stake of UK investors but enhanced the chances of a successful initial public offering on the Nasdaq stock market.

Statistics:

  • Sterilox's revenues are expected to top £10m in 2003, up from zero in 2001.
  • The company has established its product in 100 NHS hospitals, giving it almost 25% of the market.
  • Sterilox's US parent has been cleared by the US Food and Drug Administration and has been certified for use in US food equipment.
  • The company has a staff of fewer than 70, and its UK operation employs around 50 people.
  • Sterilox has received investment from Equinox Securities, a UK private equity firm, and has brought in David Anderson, 51, a US medical technology veteran, as group chief executive.

Sources:

  • The article cites the following sources:

+ "Stoke-on-Trent's Sterilox Technologies..." is a direct quote from the article

+ "Ian Woodcock, a former British paratrooper..." is mentioned as the source of the idea for Sterilox

+ "Rob Hartley, who heads Sterilox's UK operation..." is quoted as the current director of the company

+ "Equinox has raised money for Sterilox through a US private placement..." is mentioned as a source of funding

+ "David Anderson, 51, a US medical technology veteran..." is cited as the current group chief executive of Sterilox

+ "The company has a staff of fewer than 70..." is a direct quote from the article

Read more